Worldwide has extensive capabilities in global analgesia research, including experience with human experimental and clinical models for proof-of-concept in nociceptive and neuropathic pain and for registration studies to support marketing authorization in a number of acute and chronic pain indications.

Since 2008, we have been involved in the design, execution and analysis of over 20 pain syndrome trials, each of which included at least clinical monitoring or project management services provided by Worldwide. Our team has experience investigating a range of diverse pharmacological classes such as non-steroidal antiinflammatory drugs (NSAIDS), cyclooxygenase (COX)-2 inhibitors, opioids, conopeptides, gabapentinoids, selective or nonselective monoamine reuptake inhibitors (MAOIs), antiepileptic drugs, mitogen activated protein kinase inhibitors, and importantly, non-addictive pain compounds with novel modes of action.